318 results on '"Walpole, Euan"'
Search Results
2. Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
3. HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer
4. Development of a key performance indicator for breast cancer in Queensland, Australia
5. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
6. Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy.
7. Optimal care pathways: A national policy to improve quality of cancer care and address inequalities in cancer outcomes
8. Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes
9. Patterns of primary health care service use of Indigenous Australians diagnosed with cancer
10. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
11. Serum vitamin D decreases during chemotherapy: An Australian prospective cohort study
12. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
13. Patterns of care for ductal carcinoma in situ of the breast: Queensland's experience over a decade
14. “I’m a Survivor”: Aboriginal and Torres Strait Islander Cancer Survivors’ Perspectives of Cancer Survivorship
15. Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer
16. The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study
17. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)
18. Temporal changes in loss of life expectancy due to cancer in Australia : a flexible parametric approach
19. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature
20. HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer
21. Development of a key performance indicator for breast cancer in Queensland, Australia
22. Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting
23. The role of the GP in follow-up cancer care: a systematic literature review
24. Indigenous cancer care in Queensland, Australia: Health professionals' framing of 'difference'
25. 280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPY
26. 204. THE TUMOUR IMMUNE MICROENVIRONMENT IN OESOPHAGEAL ADENOCARCINOMA HAS PROGNOSTIC SIGNIFICANCE
27. Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
28. Princess Alexandra Hospital model of comprehensive geriatric assessment of cancer patients: Methodological and practical aspects
29. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
30. Development of key performance indicator (KPI) for real-time monitoring of treatment of early breast cancer to control socioeconomic and indigenous systemic bias.
31. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland
32. Indigenous Australians with non–small cell lung cancer or cervical cancer receive suboptimal treatment
33. End‐of‐life intravenous chemotherapy administration patterns in the treatment of Queensland lung and pancreas cancer patients: a 10‐year retrospective analysis
34. High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres
35. Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women
36. Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma
37. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review
38. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)
39. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
40. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation
41. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer
42. Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real‐world study
43. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
44. Are general practitioners getting the information they need from hospitals and specialists to provide quality cancer care for Indigenous Australians?
45. Feasibility of chemoradiation therapy with protracted infusion of5-fluorouracil for esophageal cancer patients not suitable for cisplatin
46. Research governance authorisation: the next frontier
47. Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum
48. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen
49. Clinical outcomes of vitamin D deficiency and supplementation in cancer patients
50. Bortezomib use and outcomes for the treatment of multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.